TY - JOUR
T1 - Mean Arterial Pressure Targets and Patient-Important Outcomes in Critically Ill Adults
T2 - A Systematic Review and Meta-Analysis of Randomized Trials
AU - Carayannopoulos, Kallirroi Laiya
AU - Pidutti, Andrew
AU - Upadhyaya, Yashita
AU - Alshamsi, Fayez
AU - Basmaji, John
AU - Granholm, Anders
AU - Alhazzani, Waleed
AU - Lewis, Kimberley
N1 - Copyright © 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - OBJECTIVE: To conduct a systematic review and meta-analysis to determine whether targeting a higher mean arterial pressure (MAP) compared with a lower MAP in adults with shock results in differences in patient important outcomes.DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov through May 2021.STUDY SELECTION: Titles and abstracts were screened independently and in duplicate to identify potentially eligible studies, then full text for final eligibility. We included parallel-group randomized controlled trials in adult patients with a diagnosis of shock requiring vasoactive medications. The higher MAP group was required to receive vasoactive medications to target a higher MAP as established by study authors, whereas the lower MAP group received vasoactive medications to target lower MAP.DATA EXTRACTION: In triplicate, reviewers independently extracted data using a prepiloted abstraction form. Statistical analyses were conducted using the RevMan software Version 5.3.DATA SYNTHESIS: Six randomized controlled trials (n = 3,690) met eligibility criteria. Targeting a higher MAP (75-85 mm Hg) compared with lower MAP of 65 mm Hg resulted in no difference in mortality (relative risk [RR], 1.06; 95% CI, 0.98-1.15; I2 = 0%; p = 0.12; moderate certainty. Targeting a higher MAP resulted in no difference in the risk of undergoing renal replacement therapy (RR, 0.96; 95% CI, 0.83-1.11; I2 = 24%; p = 0.57; moderate certainty); however, a subgroup analysis comparing patients with and without chronic hypertension demonstrated that a higher MAP may reduce the risk of undergoing renal replacement therapy (RR, 0.83; 95% CI, 0.71-0.98; I2 = 0%; p = 0.02).CONCLUSIONS: In conclusion, our systematic review and meta-analysis demonstrated with moderate certainty that there is no difference in mortality when a higher MAP is targeted in critically ill adult patients with shock. Further studies are needed to determine the impact of mean arterial pressure on need for renal replacement therapy in this population.
AB - OBJECTIVE: To conduct a systematic review and meta-analysis to determine whether targeting a higher mean arterial pressure (MAP) compared with a lower MAP in adults with shock results in differences in patient important outcomes.DATA SOURCES: We searched MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov through May 2021.STUDY SELECTION: Titles and abstracts were screened independently and in duplicate to identify potentially eligible studies, then full text for final eligibility. We included parallel-group randomized controlled trials in adult patients with a diagnosis of shock requiring vasoactive medications. The higher MAP group was required to receive vasoactive medications to target a higher MAP as established by study authors, whereas the lower MAP group received vasoactive medications to target lower MAP.DATA EXTRACTION: In triplicate, reviewers independently extracted data using a prepiloted abstraction form. Statistical analyses were conducted using the RevMan software Version 5.3.DATA SYNTHESIS: Six randomized controlled trials (n = 3,690) met eligibility criteria. Targeting a higher MAP (75-85 mm Hg) compared with lower MAP of 65 mm Hg resulted in no difference in mortality (relative risk [RR], 1.06; 95% CI, 0.98-1.15; I2 = 0%; p = 0.12; moderate certainty. Targeting a higher MAP resulted in no difference in the risk of undergoing renal replacement therapy (RR, 0.96; 95% CI, 0.83-1.11; I2 = 24%; p = 0.57; moderate certainty); however, a subgroup analysis comparing patients with and without chronic hypertension demonstrated that a higher MAP may reduce the risk of undergoing renal replacement therapy (RR, 0.83; 95% CI, 0.71-0.98; I2 = 0%; p = 0.02).CONCLUSIONS: In conclusion, our systematic review and meta-analysis demonstrated with moderate certainty that there is no difference in mortality when a higher MAP is targeted in critically ill adult patients with shock. Further studies are needed to determine the impact of mean arterial pressure on need for renal replacement therapy in this population.
KW - mean arterial pressure
KW - sepsis
KW - shock
KW - vasoactive agents
UR - http://www.scopus.com/inward/record.url?scp=85146697374&partnerID=8YFLogxK
U2 - 10.1097/CCM.0000000000005726
DO - 10.1097/CCM.0000000000005726
M3 - Review
C2 - 36661452
SN - 0090-3493
VL - 51
SP - 241
EP - 253
JO - Critical Care Medicine
JF - Critical Care Medicine
IS - 2
ER -